Drug intelligence / Profile preview

JNJ-8899837

Development stage: Unknown
Lead developer: Johnson & Johnson
Modality: Small Molecules
Administration: Oral

Overview

JNJ-8899837 is an orally bioavailable small molecule inhibitor of Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 (MALT1). MALT1 is a paracaspase that plays a critical role in the NF-κB signaling pathway, which is frequently dysregulated in B-cell malignancies. By inhibiting MALT1 protease activity, JNJ-8899837 aims to suppress the survival and proliferation of malignant B-cells. It is currently being developed by Johnson & Johnson for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on JNJ-8899837.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-8899837.

Explore the full profile